Shots:

• The ongoing P-lll study involves assessing of Sputnik V vaccine vs PBO in 40-000 patients in a ratio (1:3) with COVID-19. The efficacy of the vaccine is 91.4%- based on the second interim analysis of data obtained 28 days after administering the first dose
• Preliminary data from volunteers obtained 42days after the first dose (corresponds with 21days after the second dose) indicates the efficacy of the vaccine above 95%.
• The data will be published by the Gamaleya Center team in peer-reviewed medical journals. Following the completion of P-lll clinical trials- Gamaleya Center will provide access to the full clinical trial report

­ Ref: Sputnik | Image: Anadolu Agency